Please assess the completion status of the following clinical trial:

Trial Title: Estrogen for Triple Negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* histologically or cytologically confirmed breast cancer which is metastatic.~* A formalin-fixed paraffin embedded tumor block (preferred) or unstained slides must be available from either a prior biopsy of the primary tumor or a metastatic site. .~* Primary tumor or metastatic biopsy lacking estrogen and progesterone receptor and Her2 negative~* Patients must have measurable disease.~* Eastern Cooperative Oncology Group performance status 0-1.~* Patients with bone metastasis at baseline must agree to treatment with intravenous bisphosphonates~* Subjects may have had 0-4 lines of prior systemic chemotherapy or targeted therapy regimens administered for treatment of their metastatic breast cancer.~* Age \>18 years~* Life expectancy of greater than 3 months.~* Patients must have adequate organ and marrow function as defined below:~Exclusion Criteria:~* systemic chemotherapies, targeted therapies or radiotherapy for their cancer within 2 weeks prior to entering the study~* Patients receiving any other investigational agents for breast cancer treatment.~* Patients with known brain metastases are excluded 3.2.4 History of allergic reactions attributed to compounds of similar chemical or biologic composition to estradiol.~* Patients with any condition of the gastrointestinal tract that is expected to result in an inability to take oral medication~* Dysfunctional or post-menopausal vaginal bleeding.~* Uncontrolled hypercalcemia/hypocalcemia~* Prior history of or active thrombophlebitis, cerebral vascular accident, myocardial infarction, deep venous thrombosis or pulmonary embolism.~* History of or active hepatic adenoma.~* Uncontrolled intercurrent illness~* Pregnant women are excluded from this study~* Patients with bone metastasis are excluded if they are unable to receive intravenous bisphosphonate therapy due to the risk for developing hypercalcemia.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Estrogen Therapy (Type: EXPERIMENTAL): Estrogen therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).